ClinicalTrials.gg
CompletedNCT01614912Updated Apr 12, 2022Results posted

Long-term Extension Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia

A Phase 3 interventional study of SM-13496 in Schizophrenia, sponsored by Sumitomo Pharma Co., Ltd.. Completed at 4 sites in 4 countries. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2022-04-12.

Sponsored by Sumitomo Pharma Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
284
Allocation
Not applicable
Ages
18 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 39 studies testing lurasidone in Schizophrenia — none open to participants now, none under way, none of them phase 3. lurasidone · Schizophrenia.

Enrollment
13th of 39
284 · median 149
Started
2012
with 4 others
Phase 3
18 of 39
none open now
Registered
22nd of 39
by date
Lead sponsor
3 of 39
Sumitomo Pharma Co., Ltd.

Among the 39 studies testing lurasidone in Schizophrenia, this one is the 13th largest by enrollment, is one of 5 that started in 2012, is one of 18 in phase 3, and was the 22nd registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

None of the 39 studies testing lurasidone in Schizophrenia is open now. The open studies under Schizophrenia, anywhere →

About lurasidone

lurasidone: first FDA approval 2010 (LATUDA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 39 studies testing lurasidone in Schizophrenia as a file.
02

Study summary

The study evaluates the long term safety and efficacy of SM-13496 in patients with schizophrenia.

03

Conditions studied

  • Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who are considered by the investigator eligible for the present study with no significant safety concerns
  • Patients who are fully informed of and understand the objectives, procedures, and possible benefits and risks of the study and who provide written voluntarily consent to participate in the study

Exclusion criteria

Exclusion Criteria:

  • Patients who are planning pregnancy for the expected duration of the study
  • Patients who are otherwise considered ineligible for the study by the investigator
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
284 participants (actual)

Study arms

  • Experimental
    SM-13496

    Drug: SM-13496

Interventions

  • 40 or 80 mg once daily orally

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at LOCF Endpoint

    The PANSS is an interview-based measure of the severity of psychopathology in adults with psychotic disorders. The measure is comprised of 30 items and three subscales: the Positive subscale contains seven questions to assess delusions, conceptual disorganization, hallucinations behavior, excitement, grandiosity, suspiciousness/persecution, and hostility; the Negative subscale contains seven questions to assess blunted effect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, lack of motivation, and similar symptoms; and the General Psychopathology subscale addresses other symptoms such as anxiety, somatic concern, and disorientation. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS total score is the sum of all 30 items and ranges from 30 through 210. A higher score is associated with greater illness severity.

    Time frame: DB baseline and up to 32 weeks (LOCF endpoint)

Secondary outcomes

  1. Change From Baseline in the Clinical Global Impression - Severity of Illness (CGI-S) Score at LOCF Endpoint

    CGI-S is a clinician-rated assessment of the participant's current disease state on a 7-point scale, where a higher score is associated with greater severity of the disease. Baseline in the prior study (D1001056, double-blind \[DB\] baseline) was defined as baseline of the prior study. Baseline in the present study (D1001057, extension \[EXT\] baseline) was defined as Week 6 in the prior study. The last post-baseline visit data collected during the study treatment of the present study were carried forward and defined as the last observation carried forward (LOCF) endpoint.

    Time frame: DB baseline and up to 32 weeks (LOCF endpoint)

  2. Change From Baseline in PANSS Positive Subscale Score at LOCF Endpoint

    The PANSS is comprised of 30 items and three subscales. The Positive subscale contains seven questions to assess delusions, conceptual disorganization, hallucinations behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS Positive subscale score is the sum of all 7 items and ranges from 7 through 49. A higher score is associated with greater illness severity.

    Time frame: DB baseline and up to 32 weeks (LOCF endpoint)

  3. Change From Baseline in PANSS Negative Subscale Score at LOCF Endpoint

    The PANSS is comprised of 30 items and three subscales. The Negative subscale contains seven questions to assess blunted effect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, lack of motivation, and similar symptoms. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS Negative subscale score is the sum of all 7 items and ranges from 7 through 49. A higher score is associated with greater illness severity.

    Time frame: DB baseline and up to 32 weeks (LOCF endpoint)

  4. Change From Baseline in PANSS General Psychopathology Subscale Score at LOCF Endpoint

    The PANSS is comprised of 30 items and three subscales. The General Psychopathology subscale addresses other 16 symptoms such as anxiety, somatic concern, and disorientation. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS General Psychopathology subscale score is the sum of all 16 items and ranges from 16 through 112. A higher score is associated with greater illness severity.

    Time frame: DB baseline and up to 32 weeks (LOCF endpoint)

  5. Proportion of Participants With Treatment-Emergent Adverse Events (TEAEs)

    Proportion of participants with treatment-emergent adverse events. An adverse event was defined as any untoward medical occurrence in a patient treated with a medicinal (investigational) product and which did not necessarily have a causal relationship with this treatment. Treatment-emergent adverse events are defined as adverse events with a start date on or after the date of initial administration of study drug in the present study through the end of follow-up or adverse events occurring before the date of initial administration of study drug in the present study and worsening during the study treatment in the present study.

    Time frame: EXT baseline and up to 26 weeks

  6. Proportion of Participants With TEAEs Leading to Discontinuation

    Time frame: EXT baseline and up to 26 weeks

  7. Proportion of Participants With Treatment-emergent Serious Adverse Events (SAEs)

    Proportion of participants with treatment-emergent adverse events. A serious adverse event was defined as an AE that met one or more of the following criteria: Resulted in death; Was life-threatening (i.e., a patient was at immediate risk of death at the time of the event, not an event where occurrence in a more severe form might have caused death); Required hospitalization or prolongation of existing hospitalization; Resulted in persistent or significant disability or incapacity; Was a congenital anomaly or birth defect; Was an important medical event that might jeopardize the patient or might require medical intervention to prevent one of the outcomes listed above.

    Time frame: EXT baseline and up to 26 weeks

07

Results

Posted Oct 19, 2018

Participant flow

Participant flow — Overall Study
MilestoneSM-13496 (Lurasidone HCl) 40-mg or 80-mg Group
Started284
Completed159
Not completed125

Outcome measures

PrimaryChange From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at LOCF Endpoint

The PANSS is an interview-based measure of the severity of psychopathology in adults with psychotic disorders. The measure is comprised of 30 items and three subscales: the Positive subscale contains seven questions to assess delusions, conceptual disorganization, hallucinations behavior, excitement, grandiosity, suspiciousness/persecution, and hostility; the Negative subscale contains seven questions to assess blunted effect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, lack of motivation, and similar symptoms; and the General Psychopathology subscale addresses other symptoms such as anxiety, somatic concern, and disorientation. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS total score is the sum of all 30 items and ranges from 30 through 210. A higher score is associated with greater illness severity.

Time frame:
DB baseline and up to 32 weeks (LOCF endpoint)
Reported as:
Mean · units on a scale
Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at LOCF Endpoint
units on a scaleSM-13496 (Lurasidone HCl) 40-mg or 80-mg Group
Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at LOCF Endpoint-28.4 ± 22.2
SecondaryChange From Baseline in the Clinical Global Impression - Severity of Illness (CGI-S) Score at LOCF Endpoint

CGI-S is a clinician-rated assessment of the participant's current disease state on a 7-point scale, where a higher score is associated with greater severity of the disease. Baseline in the prior study (D1001056, double-blind \[DB\] baseline) was defined as baseline of the prior study. Baseline in the present study (D1001057, extension \[EXT\] baseline) was defined as Week 6 in the prior study. The last post-baseline visit data collected during the study treatment of the present study were carried forward and defined as the last observation carried forward (LOCF) endpoint.

Time frame:
DB baseline and up to 32 weeks (LOCF endpoint)
Reported as:
Mean · units on a scale
Change From Baseline in the Clinical Global Impression - Severity of Illness (CGI-S) Score at LOCF Endpoint
units on a scaleSM-13496 (Lurasidone HCl) 40-mg or 80-mg Group
Change From Baseline in the Clinical Global Impression - Severity of Illness (CGI-S) Score at LOCF Endpoint-1.46 ± 1.36
SecondaryChange From Baseline in PANSS Positive Subscale Score at LOCF Endpoint

The PANSS is comprised of 30 items and three subscales. The Positive subscale contains seven questions to assess delusions, conceptual disorganization, hallucinations behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS Positive subscale score is the sum of all 7 items and ranges from 7 through 49. A higher score is associated with greater illness severity.

Time frame:
DB baseline and up to 32 weeks (LOCF endpoint)
Reported as:
Mean · units on a scale
Change From Baseline in PANSS Positive Subscale Score at LOCF Endpoint
units on a scaleSM-13496 (Lurasidone HCl) 40-mg or 80-mg Group
Change From Baseline in PANSS Positive Subscale Score at LOCF Endpoint-8.4 ± 6.8
SecondaryChange From Baseline in PANSS Negative Subscale Score at LOCF Endpoint

The PANSS is comprised of 30 items and three subscales. The Negative subscale contains seven questions to assess blunted effect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, lack of motivation, and similar symptoms. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS Negative subscale score is the sum of all 7 items and ranges from 7 through 49. A higher score is associated with greater illness severity.

Time frame:
DB baseline and up to 32 weeks (LOCF endpoint)
Reported as:
Mean · units on a scale
Change From Baseline in PANSS Negative Subscale Score at LOCF Endpoint
units on a scaleSM-13496 (Lurasidone HCl) 40-mg or 80-mg Group
Change From Baseline in PANSS Negative Subscale Score at LOCF Endpoint-6.9 ± 5.9
SecondaryChange From Baseline in PANSS General Psychopathology Subscale Score at LOCF Endpoint

The PANSS is comprised of 30 items and three subscales. The General Psychopathology subscale addresses other 16 symptoms such as anxiety, somatic concern, and disorientation. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS General Psychopathology subscale score is the sum of all 16 items and ranges from 16 through 112. A higher score is associated with greater illness severity.

Time frame:
DB baseline and up to 32 weeks (LOCF endpoint)
Reported as:
Mean · units on a scale
Change From Baseline in PANSS General Psychopathology Subscale Score at LOCF Endpoint
units on a scaleSM-13496 (Lurasidone HCl) 40-mg or 80-mg Group
Change From Baseline in PANSS General Psychopathology Subscale Score at LOCF Endpoint-13.1 ± 11.7
SecondaryProportion of Participants With Treatment-Emergent Adverse Events (TEAEs)

Proportion of participants with treatment-emergent adverse events. An adverse event was defined as any untoward medical occurrence in a patient treated with a medicinal (investigational) product and which did not necessarily have a causal relationship with this treatment. Treatment-emergent adverse events are defined as adverse events with a start date on or after the date of initial administration of study drug in the present study through the end of follow-up or adverse events occurring before the date of initial administration of study drug in the present study and worsening during the study treatment in the present study.

Time frame:
EXT baseline and up to 26 weeks
Reported as:
Count of participants · Participants
Proportion of Participants With Treatment-Emergent Adverse Events (TEAEs)
ParticipantsSM-13496 (Lurasidone HCl) 40-mg or 80-mg Group
Proportion of Participants With Treatment-Emergent Adverse Events (TEAEs)215
SecondaryProportion of Participants With TEAEs Leading to Discontinuation
Time frame:
EXT baseline and up to 26 weeks
Reported as:
Count of participants · Participants
Proportion of Participants With TEAEs Leading to Discontinuation
ParticipantsSM-13496 (Lurasidone HCl) 40-mg or 80-mg Group
Proportion of Participants With TEAEs Leading to Discontinuation39
SecondaryProportion of Participants With Treatment-emergent Serious Adverse Events (SAEs)

Proportion of participants with treatment-emergent adverse events. A serious adverse event was defined as an AE that met one or more of the following criteria: Resulted in death; Was life-threatening (i.e., a patient was at immediate risk of death at the time of the event, not an event where occurrence in a more severe form might have caused death); Required hospitalization or prolongation of existing hospitalization; Resulted in persistent or significant disability or incapacity; Was a congenital anomaly or birth defect; Was an important medical event that might jeopardize the patient or might require medical intervention to prevent one of the outcomes listed above.

Time frame:
EXT baseline and up to 26 weeks
Reported as:
Count of participants · Participants
Proportion of Participants With Treatment-emergent Serious Adverse Events (SAEs)
ParticipantsSM-13496 (Lurasidone HCl) 40-mg or 80-mg Group
Proportion of Participants With Treatment-emergent Serious Adverse Events (SAEs)31

Adverse events

Collected over EXT baseline and up to 24 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SM-13496 (Lurasidone HCl) 40-mg or 80-mg Group1/282 (0.4%)31/282 (11%)184/282 (65.2%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventSM-13496 (Lurasidone HCl) 40-mg or 80-mg Group
SchizophreniaPsychiatric disorders17/282
HyponatraemiaMetabolism and nutrition disorders2/282
Psychotic disorderPsychiatric disorders2/282
MethaemoglobinaemiaBlood and lymphatic system disorders1/282
Acute coronary syndromeCardiac disorders1/282
Cardiac failure congestiveCardiac disorders1/282
Diabetes insipidusEndocrine disorders1/282
Gastritis erosiveGastrointestinal disorders1/282
Gastrooesophageal reflux diseaseGastrointestinal disorders1/282
Ankle fractureInjury, poisoning and procedural complications1/282
Most frequent other events
Showing 10 of 194
Most frequent other events
EventSM-13496 (Lurasidone HCl) 40-mg or 80-mg Group
InsomniaPsychiatric disorders32/282
AkathisiaNervous system disorders31/282
NasopharyngitisInfections and infestations30/282
AnxietyPsychiatric disorders23/282
NauseaGastrointestinal disorders16/282
HeadacheNervous system disorders15/282
Upper respiratory tract infectionInfections and infestations14/282
ConstipationGastrointestinal disorders10/282
TremorNervous system disorders10/282
SchizophreniaPsychiatric disorders10/282

Baseline characteristics

ITT (intent-to-treat) population

Age, Continuous
Age, Continuous(years)SM-13496 (Lurasidone HCl) 40-mg or 80-mg Group
Mean43.2 ± 13.8
Sex: Female, Male
Sex: Female, Male(Participants)SM-13496 (Lurasidone HCl) 40-mg or 80-mg Group
Female129
Male152
Region of Enrollment
Region of Enrollment(participants)SM-13496 (Lurasidone HCl) 40-mg or 80-mg Group
Japan126
Taiwan39
Korea, Republic of76
Malaysia40
08

Study locations

4 sites
  • 69 Sites
    Tokyo, Etc, Japan
  • 22 Sites
    Seoul, Etc, Korea, Republic of
  • 10 Sites
    Kuala Lumpur, Etc, Malaysia
  • 14Sites
    Taipei, Etc, Taiwan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2012, a primary completion of May 2015 and a completion of May 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2018, 3 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2012
First posted
Jun 8, 2012
Start
Aug 2012
Primary completionActual
May 2015
CompletionActual
May 2015
Results first posted
Oct 19, 2018
Last update
Apr 12, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 12, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01614912
Responsible party
Sponsor
First posted
Jun 8, 2012
Start date
Aug 2012
Primary completion
May 2015
Completion
May 2015
Results posted
Oct 19, 2018
Last update
Apr 12, 2022

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lurasidone

Start the discussion